ABVC Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

ABVC BioPharma Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerABVC

Market Cap34.2M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

ABVC BioPharma Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for PDC-1421 Capsule in Attention-Deficit Hyperactivity Disorder (ADHD) (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
ABV-1504	Major Depressive Disorder	n/a	n/a	Public pipeline row
ABV-1505	n/a	n/a	n/a	Public pipeline row
ABV-1701	Retinal Detachment	n/a	Na	Public pipeline row
PDC-1421 Capsule	Attention-Deficit Hyperactivity Disorder (ADHD)	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05202327	Phase 2	COMPLETED	99	2023-12-06
NCT05414747	Na	SUSPENDED	40	2024-12-15

Scientific Context

asset_name | ABV-1504
asset_name | ABV-1504
indication | Major Depressive Disorder
indication | Major Depressive Disorder
asset_name | ABV-1505

Want the full ABVC research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.